Physician profile

Thomas Charles Dotson

Internal Medicine · Manassas, VA

NPI 1659356079

$395.61

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$318.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $193.99 2024 Airsupra, Breztri
Abbott Laboratories $40.68 2019-2021
Exact Sciences Corporation $35.10 2024 Cologuard Collection Kit
Pfizer INC. $30.07 2023
Otsuka America Pharmaceutical, INC. $30.00 2024 Rexulti
Biohaven Pharmaceuticals, INC. $18.99 2021
Novo Nordisk INC $17.26 2021
Lilly USA, LLC $14.89 2023 Mounjaro
Amgen INC. $14.63 2024 Repatha, Otezla

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Charles Dotson

$395.61

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/346821/thomas-charles-dotson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.